AstraZeneca: Autoimmune Disease Treatment Ultomiris Met Phase 3 Trial Primary Endpoint

 AstraZeneca PLC said Thursday that its treatment for neuromyelitis optica spectrum disorder (NMOSD) Ultomiris met the primary endpoint in a Phase 3 clinical trial with a "statistically significant and clinically meaningful" reduction in the risk of relapse.

The Anglo-Swedish pharma giant said no relapse was observed in 58 patients during a treatment duration of 73 weeks.

"Every NMOSD relapse can have debilitating and irreversible consequences, so reducing relapses is critical," lead primary investigator in the trial Sean J. Pittock said.

The company said the data will be submitted to global health authorities as rapidly as possible.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-Says-Autoimmune-Disease-Treatment-Ultomiris-Met-Phase-3-Trial-Primary-Endpoint-40276688/